Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience

Hicham Skali; Hans-Henrik Parving; Patrick S Parfrey; Emmanuel A Burdmann; Eldrin F Lewis; Peter Ivanovich; Sai Ram Keithi-Reddy; Janet B McGill; John J V McMurray; Ajay K Singh; Scott D Solomon; Hajime Uno; Marc A Pfeffer; TREAT Investigators

doi:10.1161/CIRCULATIONAHA.111.030411

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience

Hicham Skali, Hans-Henrik Parving, Patrick S Parfrey, Emmanuel A Burdmann, Eldrin F Lewis, Peter Ivanovich, Sai Ram Keithi-Reddy, Janet B McGill, John J V McMurray, Ajay K Singh, Scott D Solomon, Hajime Uno, Marc A Pfeffer, TREAT Investigators

84 Citations (Scopus)

Abstract

More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association.

Original language	English
Journal	Circulation (Baltimore)
Volume	124
Issue number	25
Pages (from-to)	2903-8
Number of pages	6
ISSN	0009-7322
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.111.030411
Publication status	Published - 2011

Keywords

Aged
Anemia
Case-Control Studies
Diabetes Mellitus, Type 2
Erythropoietin
Female
Follow-Up Studies
Hematinics
Humans
Incidence
Logistic Models
Male
Middle Aged
Multivariate Analysis
Predictive Value of Tests
Prospective Studies
Renal Insufficiency, Chronic
Risk Factors
Risk Reduction Behavior
Stroke
Treatment Outcome

Access to Document

10.1161/CIRCULATIONAHA.111.030411

Cite this

Skali, H., Parving, H.-H., Parfrey, P. S., Burdmann, E. A., Lewis, E. F., Ivanovich, P., Keithi-Reddy, S. R., McGill, J. B., McMurray, J. J. V., Singh, A. K., Solomon, S. D., Uno, H., Pfeffer, M. A., & TREAT Investigators (2011). Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (Baltimore), 124(25), 2903-8. https://doi.org/10.1161/CIRCULATIONAHA.111.030411

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. / Skali, Hicham; Parving, Hans-Henrik; Parfrey, Patrick S et al.
In: Circulation (Baltimore), Vol. 124, No. 25, 2011, p. 2903-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Skali, H, Parving, H-H, Parfrey, PS, Burdmann, EA, Lewis, EF, Ivanovich, P, Keithi-Reddy, SR, McGill, JB, McMurray, JJV, Singh, AK, Solomon, SD, Uno, H, Pfeffer, MA & TREAT Investigators 2011, 'Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience', Circulation (Baltimore), vol. 124, no. 25, pp. 2903-8. https://doi.org/10.1161/CIRCULATIONAHA.111.030411

@article{92b533dad5594d28b93cb414d88a0857,

title = "Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience",

abstract = "More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association.",

keywords = "Aged, Anemia, Case-Control Studies, Diabetes Mellitus, Type 2, Erythropoietin, Female, Follow-Up Studies, Hematinics, Humans, Incidence, Logistic Models, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Prospective Studies, Renal Insufficiency, Chronic, Risk Factors, Risk Reduction Behavior, Stroke, Treatment Outcome",

author = "Hicham Skali and Hans-Henrik Parving and Parfrey, {Patrick S} and Burdmann, {Emmanuel A} and Lewis, {Eldrin F} and Peter Ivanovich and Keithi-Reddy, {Sai Ram} and McGill, {Janet B} and McMurray, {John J V} and Singh, {Ajay K} and Solomon, {Scott D} and Hajime Uno and Pfeffer, {Marc A} and {TREAT Investigators}",

year = "2011",

doi = "10.1161/CIRCULATIONAHA.111.030411",

language = "English",

volume = "124",

pages = "2903--8",

journal = "Circulation (Baltimore)",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "25",

}

TY - JOUR

T1 - Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa

T2 - the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience

AU - Skali, Hicham

AU - Parving, Hans-Henrik

AU - Parfrey, Patrick S

AU - Burdmann, Emmanuel A

AU - Lewis, Eldrin F

AU - Ivanovich, Peter

AU - Keithi-Reddy, Sai Ram

AU - McGill, Janet B

AU - McMurray, John J V

AU - Singh, Ajay K

AU - Solomon, Scott D

AU - Uno, Hajime

AU - Pfeffer, Marc A

AU - TREAT Investigators

PY - 2011

Y1 - 2011

N2 - More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association.

AB - More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association.

KW - Aged

KW - Anemia

KW - Case-Control Studies

KW - Diabetes Mellitus, Type 2

KW - Erythropoietin

KW - Female

KW - Follow-Up Studies

KW - Hematinics

KW - Humans

KW - Incidence

KW - Logistic Models

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Predictive Value of Tests

KW - Prospective Studies

KW - Renal Insufficiency, Chronic

KW - Risk Factors

KW - Risk Reduction Behavior

KW - Stroke

KW - Treatment Outcome

U2 - 10.1161/CIRCULATIONAHA.111.030411

DO - 10.1161/CIRCULATIONAHA.111.030411

M3 - Journal article

C2 - 22104547

SN - 0009-7322

VL - 124

SP - 2903

EP - 2908

JO - Circulation (Baltimore)

JF - Circulation (Baltimore)

IS - 25

ER -

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience

Abstract

Keywords

Access to Document

Fingerprint

Cite this